RxSight says preliminary unaudited fourth quarter 2022 revenue is expected to be approximately $16.1M, representing growth of approximately 91% compared to the prior year period. Consensus at $14.63M. Preliminary unaudited 2022 fiscal year revenue is expected to be approximately $49M, representing growth of approximately 117% compared to the prior year. Consensus at $47.57M. Preliminary unaudited cash, cash equivalents and short-term investments as of December 31, 2022, is expected to be $105.8M, which includes $6M in net proceeds from sales of shares of the company’s common stock sold through the company’s "at-the-market" offering during the fourth quarter of 2022.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on RXST:
- RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results
- RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
- Wells Fargo downgrades RxSight to Equal Weight on economic sensitivity
- RxSight downgraded to Equal Weight from Overweight at Wells Fargo
- Needham healthcare analyst to hold an analyst/industry conference call
